Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

| More on:
Investor sitting in front of multiple screens watching share prices

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

Collins Foods Ltd (ASX: CKF)

According to a note out of Citi, its analysts have initiated coverage on this quick service restaurant operator's shares with a buy rating and $12.80 price target. The broker believes that Collins Foods' operating earnings can nearly double between now and FY 2031. This is expected to be driven by the rollout of KFC in the Netherlands and Australia. The Collins Foods share price is trading at $10.34 on Monday afternoon.

Dicker Data Ltd (ASX: DDR)

A note out of Morgan Stanley reveals that its analysts have retained their overweight rating and $10 price target on this computer hardware and software developer's shares. This follows the release of the company's half-year update last week. While Dicker Data's revenue was softer than expected, its margins were much stronger than the broker anticipated. In light of this, Morgan Stanley feels the company is on track to achieve its earnings estimates in FY 2023. The Dicker Data share price is fetching $8.11 today.

ResMed Inc. (ASX: RMD)

Another note out of Citi reveals that its analysts have retained their buy rating on this sleep treatment company's shares with a trimmed price target of $39. While the broker was disappointed with ResMed's margin recovery, it was pleased with its strong top-line growth. And with management expecting its margins to improve in FY 2024, Citi remains positive on ResMed and retains its buy rating. The ResMed share price is trading at $29.30 today.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in Collins Foods. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Collins Foods, Dicker Data, and ResMed. The Motley Fool Australia has positions in and has recommended Dicker Data and ResMed. The Motley Fool Australia has recommended Collins Foods. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A wad of $100 bills of Australian currency lies stashed in a bird's nest.
Broker Notes

Up 40% in a year, why Macquarie expects this ASX 200 dividend stock to keep outperforming in 2026

Macquarie forecasts more outperformance from this fast-rising ASX 200 dividend stock.

Read more »

A man wearing glasses and a white t-shirt pumps his fists in the air looking excited and happy about the rising OBX share price
Broker Notes

These ASX 200 shares could rise 30% to 40%

Looking for big returns? Bell Potter thinks these shares could be the ones to buy.

Read more »

Man standing on the roof rack of a van next to boxes and gear
Broker Notes

Broker tips 30% upside for this ASX 200 stock

This ASX 200 stock could now be a buy-low option.

Read more »

Broker looking at the share price.
Broker Notes

Broker ratings on 6 ASX shares about to join the ASX 200

These 6 companies will enter the ASX 200 in the December quarter rebalance. Should you buy them?

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Man looking at digital holograms of graphs, charts, and data.
Broker Notes

3 reasons this ASX 300 tech stock is forecast to leap 83% in 2026

A leading broker expects some outsized returns from this ASX 300 tech share. Let’s see why.

Read more »

gold share price represented by speeding golden bullet
Broker Notes

Why this surging ASX All Ords gold stock is tipped to rocket another 233%

A leading broker expects outsized gains from this ASX All Ords gold stock. But not without risk.

Read more »